Abstract: This invention relates to dosage forms comprising pseudoephedrine or a salt thereof, for extended-release up to 24 hours, and process of making such dosage forms. This invention provides a non-osmotic extended-release dosage form comprising pseudoephedrine hydrochloride which can be administered to patients who need and/or desire a decongestant medication up to 24 hours. This invention also relates to dosage forms comprising pseudoephedrine or a salt thereof and cetirizine or levocetirizine or its salts thereof for extended-release up to 24 hours, and process of making such dosage forms.

Abstract: The present invention relates to a pharmaceutical composition comprising brexpiprazole or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein particle size of brexpiprazole or pharmaceutically acceptable salt thereof is D90 from about 10 ?m to about 40 ?m, particularly D90 is in the range from about 15 ?m to about 30 ?m and process of preparation of said pharmaceutical composition and its use for the adjunctive treatment of major depressive disorder (MDD) and treatment of schizophrenia.

Abstract: A controlled release dosage forms comprising zolpidem or a salt thereof to release zolpidem to induce rapid onset of sleep, and continue to release zolpidem in a controlled manner to maintain effective plasma concentrations over an extended period of time to improve sleep maintenance. The pharmaceutical controlled-release dosage form of zolpidem or a salt thereof having a dissolution profile when measured in a type I or II dissolution apparatus according to the U.S. Pharmacopoeia in 0.01M hydrochloric acid buffer at 37° C., such that less than 40% is released at the end of 30 minutes.